INS and type 2 diabetes mellitus: In obese T2DM mice (C57BL/6Ay mice, AY mice), its administration for three weeks revealed the following changes: increased glucose tolerance in OGTT, decreased fasting insulin levels and increased sensitivity to insulin, and decreased body weight and interscapular fat including brown, which indicates its activity increase [6].